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Abstract
The effects of tuberculosis (TB) on the kinetics of CD4 + T cells among HIV-infected individuals with early
combination antiretroviral therapy (cART) after TB therapy initiation are poorly characterized. We conducted a
case-control study with 15 HIV-TB-coinfected patients who initiated TB treatment and early cART, and 30
controls without TB who had similar CD4 + T cell counts and viral loads at the time of starting cART.
We compared the rate of CD4 + T cell increase for 5 years after cART. The time to CD4 + T cell increase > 250
cells/mm3 was significantly slower in HIV-TB-coinfected patients ( p = 0.015, by log rank test). HIV-TB-coin-
fected patients had significantly lower median CD4 + T cell counts at 5 years after cART ( p = 0.048). The dif-
ference in CD4 + T cell increase was observed only during the first 6 months after cART initiation ( p = 0.002).
These data suggest that TB slows the rate of CD4 + T cell recovery at an early period after cART. The effects of TB
on the long-term immunity of HIV-infected patients should be further evaluated.
Introduction
Tuberculosis (TB) is one of the most common opportu-nistic diseases, and in developing countries, it is the most
common cause of death in patients infected with human im-
munodeficiency virus (HIV).1 The number of patients coin-
fected with TB and HIV continues to grow rapidly.2 TB
accelerates the progression ofHIV infection, with an increased
viral load, a fall in CD4+ T cell counts, and increased mor-
tality.3–6 The immunological environment during active TB
infection is characterized by cytokine and chemokine irregu-
larities that are believed to increase T cell activation, enhance
HIV replication, and result in a dysfunctional immune
response.7–11
Some prospective studies have evaluated the optimal time
for initiating combination antiretroviral therapy (cART) in
HIV/TB-coinfected persons,12–14 and the studies demon-
strated a mortality reduction among those starting cART
during the early part of TB therapy compared to those who
started later or after completion of TB therapy. The current
WHOguideline recommends that cART should be initiated as
soon as TB therapy is tolerated, ideally as early as 2weeks and
not later than 8 weeks, regardless of CD4 + T cell counts.15
The immunological effects of cART for HIV-infected pa-
tients, including reduction in viral load and restoration of
CD4 + T cells, are well recognized.7,16,17 During CD4 + T cell
recovery, the initial increase is rapid and usually lasts 3–6
months, followed by a phase of slower CD4+ T cell count
recovery.18 However, in HIV/TB-coinfected patients, the
initial increase inCD4 + T cell count may not be rapid under
the influence of TB coinfection.
The effects of TB on the kinetics of CD4 + T cells among
HIV-infected patients on early cART are poorly characterized.
Especially, little is known about the study on the long-term
effect of TB on CD4 + T cell recovery in HIV/TB-coinfected
patients with early cART after TB therapy initiation. There-
fore, we investigated the effects of TB on the kinetics of CD4 +
T cell recovery among HIV/TB-coinfected patients with sus-
tained viral suppression after early cART.
Materials and Methods
Study population
HIV-1-infected patients who continued cART formore than
5 years at a tertiary-care teaching hospital in Seoul, South
Korea were included. Patients who were 18 years old or older
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at treatment initiation, and maintained a sustained sup-
pressed viral load (HIV RNA < 400 copies/ml) after 6 months
on cART, were eligible for this study. Patients who had any
treatment interruptions formore than 1monthwere excluded.
CD4 + T cell counts were evaluated at least every 6 months
(within a window of – 1 month). TB was defined as the iso-
lation of Mycobacterium tuberculosis from a clinical specimen,
the demonstration of acid-fast bacilli in a clinical specimen, or
a histopathological lesion when a culture was not available in
a person with signs or symptoms compatible with TB, or ev-
idence of disease resolution when treatment with two or more
anti-TB medications was prescribed and the patients were
followed-up.
Study design
A retrospective case-control study was conducted. The
case group included 15 HIV-TB-coinfected patients. All
subjects in the case group started early cART within 8
weeks after the initiation of TB treatment. The regimen of
anti-TB treatment was 2 months of isoniazid+ rifampicin/
rifabutin + ethambutol +pyrazinamide, and then isonia-
zid + rifampicin/rifabutin + ethambutol. Thirty HIV-infected
patients without TB who had similar CD4 + T cell counts
( – 5 cells/mm3) and viral loads (– 0.1 log10 copies/ml) at
the time of starting cART were selected as the control
group. All enrolled patients were ART naive at the start of
cART. We estimated the median time to reach a CD4 + T
cell increase greater than 250 cells/mm3 after cART initia-
tion, and the median times of the two groups were com-
pared. The median times to reach a CD4 +T cell recovery
greater than 250 cells/mm3 after cART initiation in the case
and control groups were 18 and 6 months, respectively.
Based on these numbers, we could expect to have 0.91
power with enrolled HIV-1-infected patients. We also esti-
mated the rate of CD4 + T cell recovery for every 6 months
since the initiation of cART, and compared the rates of the
two groups using a linear mixed model. This study was
approved by the Institutional Review Board of the hospital
(IRB #4-2011-0478).
Study variables
The following variables were assessed: age at the initia-
tion of cART (years); gender; type of tuberculosis; reported
route of infection; prior acquired immunodeficiency syn-
drome (AIDS) diagnosis at cART initiation; hepatitis B or C
coinfection; cART regimens [two nucleoside analog reverse
transcriptase inhibitors (NRTIs) +nonnucleoside reverse
transcriptase inhibitor (NNRTI), two NRTIs +protease in-
hibitor (PI), or other combination] at cART initiation; CD4 +
T cell count (cells/mm3); CD8 + T cell count (cells/mm3);
and HIV viral load (log10 copies/ml) at cART initiation.
Statistical analysis
Continuous variables and categorical data were analyzed
using independent sample t-tests and chi-square tests, re-
spectively. Kaplan–Meier analysis was used to estimate the
time to reach a CD4 + T cell recovery greater than 250 cells/
mm3. The rate of CD4 + T cell increase per year was estimated
using linear mixed model. All p-values were two-tailed, and a
p-value < 0.05 was considered statistically significant. All of
the statistical analyses were performed using SAS ver. 9.2
(SAS Institute, Inc., Cary, NC). In addition, a post hoc power
analysis was performed using PASS ver. 11 (NCSS, LLC,
Kaysville, UT).
Results
Characteristics of the study population
There were no significant differences in demographic or
clinical characteristics between the two groups (Table 1).
Table 1. Clinical Characteristics of HIV-Infected Individuals With or Without Tuberculosis
Case group Control group
Variables (N = 15) (N = 30) p-value
Male gender (%) 15 (100) 25 (83.3) 0.153





Mode of transmission (%)
Homosexual contacts 5 (33.3) 11 (36.7) 1.000
Heterosexual contacts 3 (20.0) 8 (26.7) 0.756
Bisexual contacts 0 (0.0) 1 (3.3) 1.000
Unknown 6 (40.0) 8 (26.7) 0.356
Pre-cART CD4 + T cell count, median (IQR), cells/mm3 114 (17–230) 114 (17–231) 1.000
Pre-cART VL, median (IQR), log10 copies/ml 5.36 (4.72–5.69) 5.31 (3.88–6.30) 0.921
Initial cART (%)
PI-based 5 (33.3) 16 (53.3) 0.342
NNRTI-based 10 (66.7) 14 (46.7) 0.342
HBV coinfection at starting cART (%) 0 (0.0) 1 (3.3) 1.000
TB, tuberculosis; HIV, human immunodeficiency virus; cART, combination antiretroviral therapy; IQR, interquartile range; VL, viral load;
PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; HBV, hepatitis B virus.
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The time to reach a CD4+ T cell recovery greater than
250 cells/mm3 between HIV-T -coinfected patients
and HIV-monoinfected patients receiving cART therapy
We estimated the median time to reach a CD4+ T cell re-
covery greater than 250 cells/mm3 after cART initiation, and
the median times of the two groups were compared. The case
group had a longer median time than the control group (18
and 6 months, respectively), and the Kaplan–Meier curve
summarizing the time to a CD4 + T cell increase greater than
250 cells/mm3 indicated that the rate of CD4+ T cell recovery
was slower forHIV-TB-coinfected thanmonoinfected patients
( p= 0.015, by log rank test) (Fig. 1).
Changes in median CD4+ T cell counts between
HIV-TB-coinfected patients and HIV-monoinfected
patients receiving cART therapy
To better evaluate whether the effect of TB on the rate of
increasing CD4 + T cell counts was dependent on time after
cART, we estimated the rate of CD4 + T cell recovery every 6
months after initiating cART, and compared the median
CD4 + T cell counts of the two groups using a linear mixed
model. HIV-TB-coinfected patients had significantly lower
median CD4 + T cell counts at 5 years after cART initiation
( p= 0.048). However, the difference in CD4 + T cell recovery
was observed only during the first 6 months after cART ini-
tiation ( p = 0.002), and not from 6 months to 5 years (Fig. 2).
Discussion
We showed thatHIV-TB-coinfected patients with sustained
viral suppression after early cART took a longer time to reach
a CD4 + T cell count increase > 250 cells/mm3 and had sig-
nificantly lower median CD4 + T cell counts at 5 years after
early cART initiation compared to HIV monoinfected pa-
tients. Moreover, coinfected patients had a slower rate of
CD4 + T cell recovery, but the difference was observed only
during the early period after cART initiation.
Importantly, we showed long-term effects of TB on im-
mune restoration during sustained viral suppression after
early cART. Although the current WHO guideline recom-
mends that cART should be initiated as soon as TB therapy is
tolerated, ideally as early as 2 weeks and not later than 8
weeks with data favoring early cART,15 there have been few
studies of the long-term ( > 5 years) effects of TB on the kinetics
of CD4 + T cell recovery among HIV-infected patients with
sustained viral suppression after early cART. A recent study
by Hermans and colleagues showed that patients with inci-
dent TB within 12 months after cART had significantly lower
median CD4 + T cell counts at 2 years compared to patients
who were TB free throughout the follow-up period.19 How-
ever, it was not clear whether cART initiation was later than 8
weeks after TB therapy.
We also showed a lower rate of CD4+ T cell recovery for
HIV-TB-coinfected patients only during the initial period
after early cART. Although the underlying mechanisms of
immunological nonresponse in HIV-TB coinfection are not
understood, one study has suggested that a complex model
of immune activation, T cell turnover, and homeostatic
regulation is responsible for CD4 + T cell loss.20 In partic-
ular, excessive T cell destruction due to T cell activation in
HIV-TB-coinfected patients plays an important role, and
has been shown to persist even after virological suppression
occurs.21–23
Our data suggest that TB in HIV-infected patients influ-
ences the redistribution of lymphocytes during the early
phase of immune restoration, and the effects of TB on immune
restoration are not overt after the treatment of TB. Generally,
in HIV-infected patients, CD4+ T cell recovery in response to
cART is thought to be biphasic, with an initial rapid increase
during the first 3–6 months after cART initiation, due to the
redistribution of cells located within the lymph reticular sys-
tem. This is followed by a slower recovery, thought to be due
to the generation of naive CD4 + T cells through cell division
or from the thymus.18,24,25 Further study of the effects of TB on
the peripheral redistribution of CD4 + T cells and generation
of naive CD4 + T cells through cell division or from the thymus
after cART initiation is needed.
FIG. 1. Cumulative probability of CD4 + T cell increase
> 250 cells/mm3 from baseline.
FIG. 2. Changes in median CD4 + T cell counts in HIV-TB-
coinfected and HIV-monoinfected patients receiving combi-
nation antiretroviral therapy.
228 KU ET AL.
In our study, NNRTI-based regimens were used more fre-
quently than PI-based regimens as an initial cART for HIV/
TB-coinfected patients. This was due to drug interactions
between protease inhibitors and rifamycin.26 Thus, the rate of
CD4 + T cell recovery might have been influenced by this
difference in initial cART regimens. However, several studies
have reported that initial treatment with either an NNRTI-
based regimen resulted in similar immunological outcomes in
long-term antiretroviral management in treatment-naive pa-
tients.27–29 Additionally, the mean duration of TB treatment
was 11– 3.3 (mean – standard deviation) months in this study.
TB treatment might influence the slow CD4 + T cell recovery
phase.
Our study has several limitations. First, the sample of HIV-
TB-coinfected patients was collected from a single center.
Second, the sample size was small. Third, as in all retrospec-
tive studies, there was the potential for bias and inaccurate
data collection. Further prospective studies with larger pa-
tient populations involving multiple centers are necessary to
ascertain more accurately the relevant influencing factors.
In conclusion, HIV/TB-coinfected patients with sustained
viral suppression after early cART took a longer time to reach
a CD4+ T cell count > 250 cells/mm3 and seem to have a
slower rate of CD4 + T cell increase during the early period
after cART, compared to HIV-monoinfected patients. How-
ever, the slower CD4 + T cell increase was observed only
during the first 6 months after cART initiation. As it is un-
certain whether this long-lasting immunosuppressive effect of
TB coinfection has a real influence on immunological function
in HIV-infected individuals, further study is needed.
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